Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines.

[1]  Y. DeClerck,et al.  Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells , 1996, Journal of cellular physiology.

[2]  A. Rafe,et al.  TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. , 1996, Experimental cell research.

[3]  G. Sledge,et al.  Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. , 1995, Journal of the National Cancer Institute.

[4]  Bonnie F. Sloane,et al.  Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. , 1994, Cancer research.

[5]  Y. DeClerck,et al.  Protease inhibitors: role and potential therapeutic use in human cancer. , 1994 .

[6]  M. Lippman,et al.  Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. , 1993, Journal of the National Cancer Institute.

[7]  A. Bridges,et al.  Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. , 1993, Cancer research.

[8]  D. Miles,et al.  Activity of type IV collagenases in benign and malignant breast disease. , 1993, British Journal of Cancer.

[9]  F. Balkwill,et al.  A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. , 1993, Cancer research.

[10]  R. Dickson,et al.  The role of cathepsin D in the invasiveness of human breast cancer cells. , 1993, Cancer research.

[11]  N. Brünner,et al.  The nude mouse as an in vivo model for human breast cancer invasion and metastasis. , 1993, Breast Cancer Research and Treatment.

[12]  H. Kobayashi,et al.  Modulation of Urokinase-type Plasminogen Activator and Ovarian Cancer Cell Invasion by in Vitro Inhibition of Updated Version Citing Articles E-mail Alerts Inhibition of in Vitro Ovarian Cancer Cell Invasion by Modulation of Urokinase- Type Plasminogen Activator and Cathepsin B , 2022 .

[13]  Robert Clarke,et al.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines , 1992, Journal of cellular physiology.

[14]  Bonnie F. Sloane,et al.  Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. , 1992, The Biochemical journal.

[15]  Bonnie F. Sloane,et al.  A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells , 1992, Melanoma research.

[16]  A. Doherty,et al.  Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors. , 1992, Journal of medicinal chemistry.

[17]  L. R. Ferreira,et al.  Evaluation of different staining procedures for the quantification of fibroblasts cultured in 96-well plates. , 1991, Analytical biochemistry.

[18]  L. Lund,et al.  The urokinase receptor and regulation of cell surface plasminogen activation. , 1990, Cell differentiation and development : the official journal of the International Society of Developmental Biologists.

[19]  P. Pujol,et al.  Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. , 1990, Oncogene.

[20]  Bonnie F. Sloane,et al.  Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors. , 1990, Cancer research.

[21]  I. Fidler,et al.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. , 1990, Cancer research.

[22]  H. Rochefort,et al.  Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. , 1990, Cancer research.

[23]  L. Liotta,et al.  Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. , 1990, The American journal of pathology.

[24]  D. Woolley,et al.  A new cell line (8701-BC) from primary ductal infiltrating carcinoma of human breast. , 1989, British Journal of Cancer.

[25]  S. Yagel,et al.  Suppression by cathepsin L inhibitors of the invasion of amnion membranes by murine cancer cells. , 1989, Cancer research.

[26]  A. Vaheri,et al.  Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants , 1989, The Journal of cell biology.

[27]  J. Kellen,et al.  Antimetastatic effect of amiloride in an animal tumour model. , 1988, Anticancer research.

[28]  H. Rochefort,et al.  In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. , 1988, Cancer research.

[29]  A. Cuschieri,et al.  Inhibition of proteinase-like peptidase activities in serum and tissue from breast cancer patients. , 1988, Anticancer research.

[30]  Y. Iwamoto,et al.  Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. , 1988, Cancer research.

[31]  K. Imahori,et al.  Thiol protease-specific inhibitor E-64 arrests human epidermoid carcinoma A431 cells at mitotic metaphase. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. Katzenellenbogen,et al.  Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. , 1988, Journal of steroid biochemistry.

[33]  D. Belin,et al.  Amiloride selectively inhibits the urokinase‐type plasminogen activator , 1987, FEBS letters.

[34]  K. Kato,et al.  Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. , 1987, Cancer research.

[35]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[36]  C. Yee,et al.  Degradation of endothelial basement membrane by human breast cancer cell lines. , 1986, Cancer research.

[37]  Y. Kikuchi,et al.  Adjuvant Effects of Tranexamic Acid to Chemotherapy in Ovarian Cancer Patients with Large Amount of Ascites , 1986, Acta obstetricia et gynecologica Scandinavica.

[38]  E. Plow,et al.  Binding and activation of plasminogen on the platelet surface. , 1985, The Journal of biological chemistry.

[39]  H. Fritz,et al.  Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. , 1983, Arzneimittel-Forschung.

[40]  A. Barrett,et al.  L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. , 1982, The Biochemical journal.

[41]  A. Barrett.  Cathepsin D and other carboxyl proteinases , 1977 .

[42]  A. Fletcher,et al.  xi-Aminocaproic acid: an inhibitor of plasminogen activation. , 1959, The Journal of biological chemistry.